COMMUNIQUÉS West-GlobeNewswire

-
Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA
22/01/2019 -
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
22/01/2019 -
TG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma
22/01/2019 -
IRADIMED CORPORATION to Hold 2018 Fourth Quarter Financial Results Conference Call on February 6th
22/01/2019 -
Voyager Therapeutics Appoints Robert Hesslein as General Counsel
22/01/2019 -
Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB
22/01/2019 -
Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)
22/01/2019 -
FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
22/01/2019 -
MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns
22/01/2019 -
CorVel Announces Quarterly Earnings Release Webcast
22/01/2019 -
EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma
22/01/2019 -
Transactions in relation to share buyback program
22/01/2019 -
Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019
22/01/2019 -
Immunicum AB (publ) Announces Upcoming Investor Events in January
22/01/2019 -
ACACIA PHARMA ANNOUNCES SUPPORTIVE CARDIAC SAFETY DATA FOR BARHEMSYS™
22/01/2019 -
Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position
22/01/2019 -
Bone Therapeutics annonce ses perspectives d’affaires pour 2019 et dresse son bilan de trésorerie
22/01/2019 -
Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck
22/01/2019 -
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases
22/01/2019
Pages